NCT00244972View on ClinicalTrials.gov

Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Advanced Malignant Neoplasm
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Sorafenib Tosylate

Given PO

DRUG

Tipifarnib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00244972 - Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer | Biotech Hunter | Biotech Hunter